{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:44:53Z","timestamp":1770831893591,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,7]]},"abstract":"<jats:p>The most common cause of hyperprolactinemia is prolactinoma. In addition, it is necessary to exclude potential physiological and pharmacological factors as well as health disorders to determine the cause of hyperprolactinemia. However, few studies have linked elevated prolactin (PRL) levels to ovarian cancer (OC). OC cells can ectopically release PRL, which then attaches to PRL receptors (PRLRs) in ovarian tissue and initiates signaling cascades that induce OC carcinogenesis. Therefore, we can consider PRL as a biomarker or tumorigenesis factor for OC. Furthermore, both PRL and PRLRs are potential therapeutic targets. A 50-year-old female presented with complaints of breast enlargement, soreness, and hyperprolactinemia, in addition to advanced OC. Hyperprolactinemia along with advanced high-grade serous ovarian carcinoma. Due to the patient\u2019s fear of confined spaces, magnetic resonance imaging of the pituitary gland under general anesthesia was prescribed to rule out pituitary pathology. Magnetic resonance imaging was not performed due to the deterioration of the underlying condition, and the patient died 2.5 years after the diagnosis of OC. Hyperprolactinemia caused by OC is a rare condition for which there is a lack of literature and case studies. PRL produced by OC tissue binds to PRLRs in an autocrine or paracrine manner, initiating signaling cascades that induce OC tumorigenesis. In combination with other biomarkers, PRL may serve as a biomarker for OC. To establish the relation between OC and elevated PRL levels, additional large-scale population studies are required, with diagnostic and treatment procedures coming first.<\/jats:p>","DOI":"10.1097\/md.0000000000040585","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:01:10Z","timestamp":1739217670000},"page":"e40585","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Ovarian cancer causing hyperprolactinemia: A case report and narrative review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6340-6544","authenticated-orcid":false,"given":"Sandra","family":"\u0160akinien\u0117","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania"},{"name":"Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u017eilda","family":"Veli\u010dkien\u0117","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania"},{"name":"Institute of Endocrinology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20250210","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian cancer: an integrated review.","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"R3-20250210","first-page":"183","article-title":"Diagnostic value of serum prolactin in ovarian cancer.","volume":"4","author":"Gurashi","year":"2018","journal-title":"IBBJ"},{"key":"R4-20250210","doi-asserted-by":"crossref","first-page":"747810","DOI":"10.3389\/fendo.2021.747810","article-title":"The relevant participation of prolactin in the genesis and progression of gynecological cancers.","volume":"12","author":"Ram\u00edrez-de-Arellano","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R5-20250210","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1158\/0008-5472.CAN-08-4652","article-title":"Biological significance of prolactin in gynecologic cancers.","volume":"69","author":"Levina","year":"2009","journal-title":"Cancer Res"},{"key":"R6-20250210","doi-asserted-by":"crossref","first-page":"e0255701","DOI":"10.1371\/journal.pone.0255701","article-title":"Connections between prolactin and ovarian cancer.","volume":"16","author":"Alkharusi","year":"2021","journal-title":"PLoS One"},{"key":"R7-20250210","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/1097-0142(19871201)60:11<2690::AID-CNCR2820601119>3.0.CO;2-J","article-title":"Ectopic prolactin secretion from a gonadoblastoma.","volume":"60","author":"Hoffman","year":"1987","journal-title":"Cancer"},{"key":"R8-20250210","first-page":"130016","article-title":"Ectopic prolactin secretion secondary to an ovarian tumour.","volume":"2013","author":"Gururaj","year":"2013","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"R9-20250210","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/gyno.2001.6247","article-title":"Hyperprolactinemia complicating juveline granulosa cell tumor of the ovary.","volume":"82","author":"Santala","year":"2000","journal-title":"Gynecol Oncol"},{"key":"R10-20250210","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1001\/jama.1990.03440180078036","article-title":"Ectopic hyperprolactinemia resulting from an ovarian teratoma.","volume":"263","author":"Kallenberg","year":"1990","journal-title":"JAMA"},{"key":"R11-20250210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jendso\/bvaa035","article-title":"Ectopic prolactin secretion from a uterine leiomyoma.","volume":"4","author":"Sachdev","year":"2020","journal-title":"J Endocr Soc"},{"key":"R12-20250210","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s42399-020-00248-6","article-title":"Uterine fibroid causing hyperprolactinemia and paradoxical prolactin rise with dopamine agonist: case report and systematic review.","volume":"2","author":"Upreti","year":"2020","journal-title":"SN Compr Clin Med"},{"key":"R13-20250210","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s11102-020-01070-y","article-title":"Ectopic hyperprolactinaemia due to a malignant uterine tumor resembling ovarian sex cord tumors (UTROCST).","volume":"23","author":"Dimitriadis","year":"2020","journal-title":"Pituitary"},{"key":"R14-20250210","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0145-2126(90)90146-Z","article-title":"Hyperprolactinemia in acute myeloid leukemia and indication of ectopic expression of human prolactin in blast cells of a patient of subtype M4.","volume":"14","author":"Hatfill","year":"1990","journal-title":"Leuk Res"},{"key":"R15-20250210","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CMR.0000000000000738","article-title":"A case of hyperprolactinaemia in a patient with metastatic melanoma.","volume":"31","author":"Manning","year":"2021","journal-title":"Melanoma Res"},{"key":"R16-20250210","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1210\/jc.2014-2623","article-title":"Ectopic prolactin secretion from a perivascular epithelioid cell tumor (PEComa).","volume":"99","author":"Korytnaya","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-20250210","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/0008-5472.CAN-16-1454","article-title":"Prolactin receptor-mediated internalization of imaging agents detects epithelial ovarian cancer with enhanced sensitivity and specificity.","volume":"77","author":"Sundaram","year":"2017","journal-title":"Cancer Res"},{"key":"R18-20250210","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.celrep.2014.03.009","article-title":"Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.","volume":"7","author":"Wen","year":"2014","journal-title":"Cell Rep"},{"key":"R19-20250210","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/cancers12010024","article-title":"Activation of STAT3 and STAT5 signaling in epithelial ovarian cancer progression: mechanism and therapeutic opportunity.","volume":"12","author":"Wu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R20-20250210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.canlet.2018.07.003","article-title":"Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model.","volume":"433","author":"Karthikeyan","year":"2018","journal-title":"Cancer Lett"},{"key":"R21-20250210","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/cancers13020325","article-title":"Automated assay of a four-protein biomarker panel for improved detection of ovarian cancer.","volume":"13","author":"Walker","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R22-20250210","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1186\/s12885-021-08682-y","article-title":"Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient\u2019s plasma\u2014a prospective trial.","volume":"21","author":"Hasenburg","year":"2021","journal-title":"BMC Cancer"},{"key":"R23-20250210","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","article-title":"A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-\u03b12b in patients with recurrent epithelial ovarian cancer.","volume":"26","author":"Dijkgraaf","year":"2015","journal-title":"An Oncol"},{"key":"R24-20250210","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2022.40.16_suppl.5501","article-title":"A phase I\/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.","volume":"40","author":"Landen","year":"2022","journal-title":"J Clin Oncol"},{"key":"R25-20250210","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0959-8049(17)30375-1","article-title":"The expression of prolactin receptor and its ligands in ovarian epithelial tumours.","volume":"72","author":"Magdy","year":"2017","journal-title":"Eur J Cancer"},{"key":"R26-20250210","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.canlet.2011.06.014","article-title":"Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists.","volume":"310","author":"Tan","year":"2011","journal-title":"Cancer Lett"},{"key":"R27-20250210","doi-asserted-by":"crossref","first-page":"e0215831","DOI":"10.1371\/journal.pone.0215831","article-title":"An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation.","volume":"14","author":"Yu","year":"2019","journal-title":"PLoS One"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:01:18Z","timestamp":1739217678000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040585","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}